Acuta Capital Partners LLC Buys New Position in Liquidia Co. (NASDAQ:LQDA)

Acuta Capital Partners LLC purchased a new position in Liquidia Co. (NASDAQ:LQDA - Free Report) during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 73,500 shares of the company's stock, valued at approximately $735,000. Liquidia makes up about 0.6% of Acuta Capital Partners LLC's holdings, making the stock its 28th largest position. Acuta Capital Partners LLC owned approximately 0.10% of Liquidia as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors and hedge funds have also recently bought and sold shares of the company. California State Teachers Retirement System lifted its stake in Liquidia by 491.2% in the 1st quarter. California State Teachers Retirement System now owns 46,181 shares of the company's stock worth $681,000 after purchasing an additional 38,369 shares in the last quarter. Boston Partners purchased a new stake in Liquidia in the 1st quarter valued at $762,000. Marshall Wace LLP purchased a new stake in Liquidia in the 2nd quarter valued at $545,000. Sapient Capital LLC acquired a new stake in shares of Liquidia in the 3rd quarter worth $1,336,000. Finally, American International Group Inc. raised its holdings in shares of Liquidia by 5.2% during the 1st quarter. American International Group Inc. now owns 24,806 shares of the company's stock worth $366,000 after acquiring an additional 1,215 shares during the period. 64.54% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several equities analysts have weighed in on LQDA shares. Raymond James upgraded shares of Liquidia from an "outperform" rating to a "strong-buy" rating in a report on Monday, August 19th. Scotiabank assumed coverage on Liquidia in a research report on Wednesday, October 16th. They issued a "sector outperform" rating and a $30.00 price objective for the company. Needham & Company LLC reaffirmed a "buy" rating and issued a $19.00 price target on shares of Liquidia in a research note on Thursday, November 14th. BTIG Research cut their price objective on Liquidia from $29.00 to $25.00 and set a "buy" rating for the company in a research report on Monday, August 19th. Finally, Bank of America decreased their target price on shares of Liquidia from $24.00 to $23.00 and set a "buy" rating on the stock in a research report on Tuesday, August 20th. One analyst has rated the stock with a sell rating, one has issued a hold rating, six have issued a buy rating and two have given a strong buy rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $24.00.

Insider Buying and Selling at Liquidia

In other news, Director Caligan Partners Lp acquired 150,000 shares of the company's stock in a transaction on Friday, August 30th. The shares were bought at an average cost of $9.51 per share, with a total value of $1,426,500.00. Following the transaction, the director now owns 6,994,997 shares in the company, valued at approximately $66,522,421.47. This trade represents a 2.19 % increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CFO Michael Kaseta sold 3,892 shares of Liquidia stock in a transaction on Monday, October 14th. The stock was sold at an average price of $11.11, for a total transaction of $43,240.12. Following the sale, the chief financial officer now directly owns 311,076 shares of the company's stock, valued at approximately $3,456,054.36. This trade represents a 1.24 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 21,551 shares of company stock valued at $236,021 in the last 90 days. Company insiders own 30.10% of the company's stock.

Liquidia Price Performance

Shares of NASDAQ LQDA traded up $0.19 during midday trading on Thursday, hitting $11.61. The company's stock had a trading volume of 485,561 shares, compared to its average volume of 974,799. The firm has a market capitalization of $982.64 million, a price-to-earnings ratio of -7.12 and a beta of 0.21. The business's fifty day simple moving average is $10.67 and its two-hundred day simple moving average is $11.36. Liquidia Co. has a 1 year low of $6.82 and a 1 year high of $16.99.

Liquidia Profile

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).